WordNet
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
PrepTutorEJDIC
- =sense organ / 受信装置
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 腎性尿崩症の臨床症状および原因 clinical manifestations and causes of nephrogenic diabetes insipidus
English Journal
- Protracted treatment with MDMA induces heteromeric nicotinic receptor up-regulation in the rat brain: An autoradiography study.
- Ciudad-Roberts A1, Camarasa J1, Pubill D2, Escubedo E1.
- Progress in neuro-psychopharmacology & biological psychiatry.Prog Neuropsychopharmacol Biol Psychiatry.2014 Aug 4;53:1-8. doi: 10.1016/j.pnpbp.2014.02.014. Epub 2014 Mar 12.
- Previous studies indicate that 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) can induce a heteromeric nicotinic acetylcholine receptor (nAChR, mainly of α4β2 subtype) up-regulation. In this study we treated male Sprague-Dawley rats twice-daily for 10days with either saline or MDMA (7mg/kg) an
- PMID 24614096
- PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.
- Barbiero JK1, Santiago R1, Tonin FS1, Boschen S1, da Silva LM1, Werner MF1, da Cunha C1, Lima MM2, Vital MA3.
- Progress in neuro-psychopharmacology & biological psychiatry.Prog Neuropsychopharmacol Biol Psychiatry.2014 Aug 4;53:35-44. doi: 10.1016/j.pnpbp.2014.02.009. Epub 2014 Mar 1.
- Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The etiology and pathogenesis of PD are still unknown, however, many evidences suggest a prominent role of oxidative stress, inflam
- PMID 24593945
- Perceived location specificity in perceptual separation-induced but not fear conditioning-induced enhancement of prepulse inhibition in rats.
- Lei M1, Luo L1, Qu T2, Jia H3, Li L4.
- Behavioural brain research.Behav Brain Res.2014 Aug 1;269:87-94. doi: 10.1016/j.bbr.2014.04.030. Epub 2014 Apr 26.
- Prepulse inhibition (PPI) is the suppression of the startle reflex when the startling stimulus is shortly preceded by a non-startling stimulus (the prepulse). Previous studies have shown that both fear conditioning of a prepulse and precedence-effect-induced perceptual separation between the conditi
- PMID 24780867
Japanese Journal
- Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases
- Takuwa Yoh,Ikeda Hitoshi,Okamoto Yasuo,Takuwa Noriko,Yoshioka Kazuaki
- Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1831(1), 185-192, 2013
- … Many of these S1P actions are receptor subtype-specific. … The cross-talks include the regulation of S1P production through altered expression and activity of sphingosine kinases in fibrotic lesions, altered expression of S1P receptors, and S1P receptor-mediated transactivation of TGFβ signaling pathway. …
- NAID 120004966619
- Pathophysiological Roles of Endothelin Receptors in Cardiovascular Diseases
- OHKITA Mamoru,TAWA Masashi,KITADA Kento,MATSUMURA Yasuo
- Journal of pharmacological sciences 119(4), 302-313, 2012-08-20
- … Physiological and pathophysiological responses to ET-1 in various tissues are mediated by interactions with ET<SUB>A</SUB>- and ET<SUB>B</SUB>-receptor subtypes. … Both subtypes on vascular smooth muscle cells mediate vasoconstriction, whereas the ET<SUB>B</SUB>-receptor subtype on endothelial cells contributes to vasodilatation and ET-1 clearance. …
- NAID 10031071269
- Genetic variability of prostaglandin E2 receptor subtype EP4 gene in aspirin-intolerant chronic urticaria
- PALIKHE Nami Shrestha,SIN Hye Jung,KIM Seung Hyun,SIN Hyun Jung,HWANG Eui Kyung,YE Young Min,PARK Hae-Sim
- Journal of human genetics 57(8), 494-499, 2012-08-01
- NAID 10031056493
Related Links
- Title PROSTAGLANDIN E RECEPTOR SUBTYPE EP4 AGONIST PROTECTS COCHLEAE AGAINST NOISE-INDUCED TRAUMA( Abstract_要旨 ) Author(s) Hori, Ryusuke Citation Kyoto University (京都大学) Issue Date 2010-03-23
- This invention relates to the use of EP2 receptor subtype selective prostaglandin E2 agonists to augment bone mass including the prevention and treatment of skeletal disorders in mammals, including humans.
★リンクテーブル★
[★]
- 英
- receptor subtype
- 関
- レセプターサブタイプ
[★]
- 英
- receptor subtype
- 関
- 受容体サブタイプ
[★]